The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
本发明涉及一种新的
噻吩吡嗪化合物,其通式为(I),以及包含这些化合物的药物组合物,以及它们在预防和/或治疗可以受到Mnk1和/或Mnk2(Mnk2a或Mnk2b)及/或其变体的激酶活性抑制影响的疾病中的治疗用途。